Stocktoria
Cuprina Holdings (Cayman) LTD CUPR
Cuprina Holdings (Cayman) LTD (CUPR) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $38,789 at a -9366.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.496 |
| Retained earnings / assets | -1.086 |
| EBIT / assets | -0.568 |
| Equity / liabilities | 1.466 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| CUPR | Cuprina Holdings (Cayman) LTD | 4/9 | -2.57 | — | — |
| HSCS | HeartSciences Inc. | 1/9 | — | — | — |
| COCH | Envoy Medical, Inc. | 2/9 | — | — | — |
| SPAI | Safe Pro Group Inc. | 4/9 | 9.05 | — | — |
| AVR | Anteris Technologies Global Corp. | 2/9 | — | — | — |
| NTRB | NutriBand Inc. | 3/9 | -15.84 | — | — |
| CLGN | CollPlant Biotechnologies Ltd | 3/9 | — | — | — |
About Cuprina Holdings (Cayman) LTD
Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology company, focuses on the development and commercialization of products for the management of chronic wounds. The company manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products used as a biological debridement tool for chronic wounds under the MEDIFLY brand name. It is also developing collagen dressings, including sponges, particles, and hydrogels using bullfrog collagen derived from the valorization of abattoir waste streams; and products using medical leeches for wound treatment. The company was founded in 2019 and is based in Singapore. Cuprina Holdings (Cayman) Limited operates as a subsidiary of Cuprina Holding Pte. Ltd.
FAQ
Is CUPR financially healthy?
Cuprina Holdings (Cayman) LTD's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does CUPR pay a dividend?
No, Cuprina Holdings (Cayman) LTD does not currently pay a dividend.
How profitable is CUPR?
In FY2025, Cuprina Holdings (Cayman) LTD had a net margin of -9366.7% and a return on equity of -92.4%.
Is CUPR a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Cuprina Holdings (Cayman) LTD: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.